Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.

Smith, C H

Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. [electronic resource] - The British journal of dermatology Jul 2006 - 160-9 p. digital

Publication Type: Clinical Trial; Journal Article

0007-0963

10.1111/j.1365-2133.2006.07316.x doi


Abscess--etiology
Adult
Antibodies, Monoclonal--adverse effects
Autoantibodies--blood
Carcinoma, Basal Cell--etiology
Carcinoma, Renal Cell--etiology
Cellulitis--etiology
Female
Follow-Up Studies
Humans
Hypertension--etiology
Immunosuppressive Agents--adverse effects
Infliximab
Kidney Neoplasms--etiology
Lentigo--etiology
Liver Diseases--etiology
Male
Middle Aged
Prospective Studies
Psoriasis--drug therapy
Respiratory Tract Infections--etiology
Skin Neoplasms--etiology
Thrombocytopenia--etiology
Time Factors
Treatment Outcome
Tuberculosis--etiology
Tumor Necrosis Factor-alpha--antagonists & inhibitors